We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.


29 May 2012 By Robert Cyran

The biotech firm’s value plunged 18 pct after it admitted a basic statistics mistake, confusing relative with absolute improvement for a new drug combination for cystic fibrosis. Such a bone-headed error is careless, but comical rather than fatal. The share slump looks overdone.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)